GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (NAS:AVDL) » Definitions » Float Percentage Of Total Shares Outstanding

Avadel Pharmaceuticals (Avadel Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 93.47% (As of May. 01, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avadel Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Avadel Pharmaceuticals's float shares is 89.85 Mil. Avadel Pharmaceuticals's total shares outstanding is 96.12 Mil. Avadel Pharmaceuticals's float percentage of total shares outstanding is 93.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Avadel Pharmaceuticals's Insider Ownership is 1.87%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Avadel Pharmaceuticals's Institutional Ownership is 23.27%.


Avadel Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Avadel Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=89.85/96.12
=93.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
Executives
Thomas S Mchugh officer: Chief Financial Officer 2280 SCHUETZ ROAD, ST. LOUIS MO 63146
Mark Anthony Mccamish director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Geoffrey Michael Glass director 4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Greg J Divis director, officer: Chief Executive Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Richard J Kim officer: Chief Commercial Officer 16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Linda Palczuk director 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Peter Thornton director TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P
Douglas J Williamson officer: Chief Medical Officer AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Sandra L Hatten officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jason Vaughn officer: Sr. VP, Technical Operations 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jordan Dubow officer: Chief Medical Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael F Kanan officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
David P Gusky officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael S Anderson director, officer: Chief Executive Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15

Avadel Pharmaceuticals (Avadel Pharmaceuticals) Headlines